Premium
Astrazeneca Plc (0A4J)
LSE
Hot Features
Inscrivez-vous gratuitement pour obtenir des cotations en temps réel, des graphiques interactifs, un flux d'options en direct et plus encore.
AstraZeneca PLC 02 January 2024 2 January 2024 15:00 GMT Transparency Directive Voting rights and capital The following notification is made in accordance with the UK Financial Conduct...
AstraZeneca PLC 27 December 2023 27 December 2023 AstraZeneca to acquire Gracell, furthering cell therapy ambition across oncology and autoimmune diseases Includes clinical-stage autologous...
AstraZeneca PLC 22 December 2023 22 December 2023 Wainua (eplontersen) granted first-ever regulatory approval in the US for the treatment of adults with polyneuropathy of hereditary...
AstraZeneca PLC 14 December 2023 14 December 2023 15:00 GMT Transaction by Person Discharging Managerial Responsibilities AstraZeneca PLC (the Company) announces Anna Manz, Non-Executive Director...
AstraZeneca PLC 12 December 2023 News Release Regulatory News Service 12 December 2023 AstraZeneca to acquire Icosavax, including potential first-in-class RSV and hMPV combination vaccine with...
AstraZeneca PLC 01 December 2023 1 December 2023 15:05 GMT BLOCK LISTING SIX MONTHLY RETURN Information provided on this form must be typed or printed electronically and provided to an ris...
AstraZeneca PLC 01 December 2023 1 December 2023 15:00 GMT Transparency Directive Voting rights and capital The following notification is made in accordance with the UK Financial Conduct...
AstraZeneca PLC 01 December 2023 1 December 2023 Update on CRYSTALIZE evidence trials Discontinuation of STABILIZE-CKD and DIALIZE-Outcomes Phase III trials AstraZeneca has decided to discontinue...
AstraZeneca PLC 23 November 2023 23 November 15:00 GMT Transaction by Person Discharging Managerial Responsibilities AstraZeneca PLC (the Company) announces that, on 22 November, it was notified...
AstraZeneca PLC 17 November 2023 17 November 2023 Truqap (capivasertib) plus Faslodex approved in the US for patients with advanced HR-positive breast cancer First-in-class AKT inhibitor has...
| Période | Variation | Variation % | Ouver. | Haut | Bas | Moyenne Vol. Quot. | VWAP | |
|---|---|---|---|---|---|---|---|---|
| 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | DE |
| 4 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | DE |
| 12 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | DE |
| 26 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | DE |
| 52 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | DE |
| 156 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | DE |
| 260 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | DE |
| Aucune Discussion Trouvée |
| Ajouter une Discussion |
Les dernières valeurs consultées apparaîtront dans cette boîte, vous permettant de choisir facilement les titres vus auparavant.
Assistance: support@advfn.fr
En accédant aux services disponibles de ADVFN, vous acceptez les Conditions Générales de ADVFN Conditions Générales
